Shares of Selecta Biosciences Inc (NASDAQ:SELB) shot up 41% during trading on Monday following a stronger than expected earnings report. The stock traded as high as $3.34 and last traded at $3.06. 1,788,645 shares traded hands during trading, an increase of 183% from the average session volume of 632,266 shares. The stock had previously closed at $2.17.

The company reported ($0.65) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.75) by $0.10. The firm had revenue of $0.90 million during the quarter.

SELB has been the subject of several research analyst reports. Canaccord Genuity lowered their target price on shares of Selecta Biosciences from $25.00 to $13.00 and set a “buy” rating for the company in a report on Monday. Zacks Investment Research cut shares of Selecta Biosciences from a “buy” rating to a “hold” rating in a report on Thursday, January 10th. Needham & Company LLC lowered their target price on shares of Selecta Biosciences to $12.00 and set a “buy” rating for the company in a report on Monday, January 28th. Stifel Nicolaus restated a “buy” rating and issued a $7.00 target price on shares of Selecta Biosciences in a report on Friday, March 15th. Finally, Mizuho lowered their target price on shares of Selecta Biosciences to $4.00 and set a “buy” rating for the company in a report on Monday, February 4th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $11.61.

In related news, Director Amir Nashat bought 1,166,666 shares of the stock in a transaction dated Friday, January 25th. The stock was acquired at an average price of $1.50 per share, for a total transaction of $1,749,999.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 25.20% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its holdings in shares of Selecta Biosciences by 17.9% in the 4th quarter. Geode Capital Management LLC now owns 175,308 shares of the company’s stock valued at $466,000 after buying an additional 26,568 shares in the last quarter. FMR LLC boosted its stake in Selecta Biosciences by 23.5% during the 4th quarter. FMR LLC now owns 345,046 shares of the company’s stock worth $918,000 after purchasing an additional 65,623 shares during the period. Two Sigma Advisers LP boosted its stake in Selecta Biosciences by 18.3% during the 4th quarter. Two Sigma Advisers LP now owns 54,900 shares of the company’s stock worth $146,000 after purchasing an additional 8,500 shares during the period. Two Sigma Investments LP boosted its stake in Selecta Biosciences by 87.8% during the 4th quarter. Two Sigma Investments LP now owns 200,498 shares of the company’s stock worth $533,000 after purchasing an additional 93,719 shares during the period. Finally, Barclays PLC boosted its stake in Selecta Biosciences by 87.6% during the 4th quarter. Barclays PLC now owns 12,661 shares of the company’s stock worth $34,000 after purchasing an additional 5,911 shares during the period. Institutional investors and hedge funds own 46.73% of the company’s stock.

The company has a market capitalization of $48.76 million, a price-to-earnings ratio of -0.86 and a beta of 1.55.

TRADEMARK VIOLATION WARNING: “Selecta Biosciences (SELB) Shares Up 41% Following Earnings Beat” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/selecta-biosciences-selb-shares-up-41-following-earnings-beat/2902867.html.

About Selecta Biosciences (NASDAQ:SELB)

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.

Recommended Story: How does inflation affect different investments?

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.